JEFFERIES 2014: Abiomed sees growth beyond Impella approval
This article was originally published in Clinica
Executive Summary
The upcoming expected US premarket approval (PMA) of Abiomed’s Impella 2.5 percutaneous heart pump will set up an extended growth cycle for the company as more product approvals follow in its wake. That was the conclusion of analyst Raj Denhoy following the Jefferies healthcare conference held in London on 19-20 November.
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.